Lithium carbonate in the management of cannabis withdrawal: A randomized placebo-controlled trial in an inpatient setting

Psychopharmacology

Volumn 231, Issue 24, 2014, Pages 4623-4636

  Johnston, Jennifer ^a   Lintzeris, Nicholas ^a,b   Allsop, David J ^a   Suraev, Anastasia ^a   Booth, Jessica ^a   Carson, Dean S ^a   Helliwell, David ^c   Winstock, Adam ^d   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^c Drug and Alcohol North Coast Area   (Australia)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Abstinence; Cannabinoids; Cannabis; Cannabis withdrawal; Lithium; Marijuana; Oxytocin

Indexed keywords

CANNABINOID; CANNABIS; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OXYTOCIN;

ADULT; APPETITE; BLOOD; CANNABIS SMOKING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; APPETITE; CANNABINOIDS; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INPATIENTS; LITHIUM CARBONATE; MALE; MARIJUANA SMOKING; MIDDLE AGED; OXYTOCIN; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84938626882     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3611-5     Document Type: Article

References (54)

1. AIHW (2012) Alcohol and other drug treatment services in Australia 2010-11: report on the national minimum data set drug treatment series no 18. Australian Institute of Health and Welfare, Canberra
2. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ (2011) The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and stress. Drug Alcohol Depend 119:123-129
3. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, Budney AJ (2012) Quantifying the clinical significance of cannabis withdrawal. PLoS ONE 7:e44864
4. Allsop DJ, Dunlop AJ, Sadler C, Rivas GR, McGregor I, Copeland J (2014a) Changes in cigarette and alcohol use during cannabis abstinence. Drug Alcohol Depend 138:54-60
5. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor I (2014b) A randomized controlled trial of nabiximols (Sativex®) as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiatry 71(3):281-291
6. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text rev. American Psychiatric Association, Washington, DC
7. Bell ML, Fairclough DL (2013) Practical and statistical issues in missing data for longitudinal patient reported outcomes. Stat Methods Med Res 19 February 2013
8. Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA (2013) Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem 59:519-526
9. Bowen R, McIlwrick J, Baetz M, Zhang X (2005) Lithium and marijuana withdrawal. Can J Psychiatry 50:240-241
10. Budney AJ, Moore BA et al (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112(3):393-402
11. Carson DS, Bosanquet DP, Carter CS, Pournajafi-Nazarloo H, Blaszczynski A, McGregor IS (2012) Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. Exper Clin Psychopharmacol 20:497-503
12. Caswell A (2005) MIMS annual 2005. CMPMedica, Sydney
13. Copeland J, Swift W (2009) Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 21:96-103
14. Copeland J, Gilmour S, Gates P, Swift W (2005) The cannabis problems questionnaire: factor structure, reliability, and validity. Drug Alcohol Depend 80:313-319
15. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA (2006) Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 15:8-14
16. Cui S, Bowen RC, Gu G, Hannesson DK, Yu PH, Zhang X (2001) Prevention of cannabinoid withdrawal syndrom by lithium: involvement of oxytocinergic neuronal activation. J Neurosci 21:9867-9876
17. Danovitch I, Gorelick DA (2012) State of the art treatments for cannabis dependence. Psychiatr Clin North Am 35:309-326
18. EMCDDA (2012) Annual Report 2012: the state of the drugs problem. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg
19. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J (1995) The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90:607-614
20. Grandjean EM, Aubry JM (2009) Lithium: updated human knowledge using an evidence-based approach: Part III. Clinical safety. CNS Drugs 23:397-418
21. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW (2013) Nabilone decreases marijuana withdrawal and a laboratory measures of marijuana relapse. Neuropsychopharmacology 2013 Feb 26
22. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF (2008) Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 69:1354-1363
23. Kagerbauer SM, Martin J, Schuster T, Blobner M, Kochs EF, Landgraf R (2013) Plasma oxytocin and vasopressin do not predict neuropeptide concentrations in human cerebrospinal fluid. J Neuroendocrinol 25:668-673
24. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL, Huestis MA (2009) Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 33:469-477
25. Keck PE Jr, McElroy SL (2002) Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 63(Suppl 4):3-11
26. Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM (2013) A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-ocurring cannabis dependence and depressive disorders. Addiction 108:1084-1094
27. Lovibond SH, Lovibond PF (1995) Manual for the depression anxiety and stress scales, 2nd edn. Psychology Foundation, Sydney
28. Maddock C, Babbs M (2006) Interventions for cannabis misuse. Adv Psychiatr Treat 12:432-439
29. Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G (2003) Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 13:179-190
30. Martin G, Copeland J, Gates P, Gilmore S (2006) The severity of dependence scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend 83:90-93
31. Mason BJ, Crean R et al (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37(7):1689-1698
32. McCullough ME, Churchland PS, Mendez AJ (2013) Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev 37:1485-1492
33. McGregor IS, Bowen MT (2012) Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav 61:331-339
34. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358-368
35. McRae-Clark AL, Carter RE, Killeen T, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT (2009) A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 105:132-138
36. McRae-Clark AL, Baker NL, Maria MM, Brady KT (2013) Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl) 228:623-631
37. Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov-Polevoi A, Casey RL, Fender T, Garbutt JC (2013) Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 37:484-489
38. Preuss UW, Watzke AB et al (2010) Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend 106(2-3):133-141
39. Quality Metric (2002) Short form (SF) - 12 version 2. Quality Metric, Lincoln, RI
40. Ramaekers JG, Kauert G et al (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23(3):266-277
41. Rubin D (1976) Inference and missing data. Biometrika 63:581-592
42. SAMHSA (2009) Treatment episode data set (TEDS): 1997-2007. National admissions to substance abuse treatment services. Substance Abuse and Mental Health Services Administration Office of Applied Studies, Rockville, MD
43. Saunders JB, Aasland OG, Babor TF, de la Puente JR, Grant M (1993) Development of the alcohol use disorders screening test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction 88:791-804
44. Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3-15
45. Szeto A, McCabe PM, Nation DA, Tabak BA, Rossetti MA, McCullough ME, Schneiderman N, Mendez AJ (2011) Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom Med 73:393-400
46. Thams P, Geisler A (1980) Dissociation by lithium of hormone-induced formation of cyclic AMP and release of glycerol in isolated rat fat cells. Acta Pharmacol Toxicol (Copenh) 46:382-387
47. UNODC (2011) World Drug Report United Nations Publications, No E 11 XI 10. United National Office of Drugs and Crime, Vienna
48. Weinstein AM, Gorelick DA (2011) Pharmacological treatment of cannabis dependence. Curr Pharm Des 17:1351-1358
49. WHO (2000) Australian WHOQOL-100, WHOQOL-BREF and CA-WHOQOL instruments: user's manual and interpretation guide (the WHOQOL study). Melbourne WHOQOL Field Study Centre, University of Melbourne Department of Psychiatry, St Vincent's Mental Health Service, Melbourne
50. WHO (2004) The World Health Organization quality of life (WHOQOL) - BREF. WHO, Geneva
51. Winstock A, Lea T, Copeland J (2009) Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol (Oxf) 23:84-93
52. Zaragosi LE, Wdziekonski B, Fontaine C, Villageois P, Peraldi P, Dani C (2008) Effects of GSK3 inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biol 9:11
53. Zhang P (2003) Multiple imputation: theory and method. Int Stat Rev 71:581-592
54. Zhang G, Zhang Y, Fast DM, Lin Z, Steenwyk R (2011) Ultra sensitive quantitation of endogenous oxytocin in rat and human plasma using a two-dimensional liquid chromatography-tandem mass spectrometry assay. Anal Biochem 416:45-52